TEVA PHARMACEUTICAL FIN LLC's ticker is and the CUSIP is 88163VAE9. A total of 44 filers reported holding TEVA PHARMACEUTICAL FIN LLC in Q2 2014. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $6,522,000 | +0.1% | 6,067,000 | 0.0% | 0.24% | -2.0% |
| Q1 2017 | $6,514,000 | -2.3% | 6,067,000 | 0.0% | 0.25% | -0.4% |
| Q4 2016 | $6,670,000 | -8.1% | 6,067,000 | -0.3% | 0.25% | -3.1% |
| Q3 2016 | $7,254,000 | -10.6% | 6,088,000 | -5.8% | 0.26% | -12.2% |
| Q2 2016 | $8,111,000 | -15.6% | 6,460,000 | -12.4% | 0.29% | -6.4% |
| Q1 2016 | $9,609,000 | -34.2% | 7,378,000 | -20.7% | 0.31% | -33.8% |
| Q4 2015 | $14,598,000 | +3.8% | 9,299,000 | -10.2% | 0.47% | +14.2% |
| Q3 2015 | $14,070,000 | -33.0% | 10,357,000 | -31.0% | 0.42% | -22.3% |
| Q2 2015 | $20,989,000 | +76.6% | 15,007,000 | +87.6% | 0.53% | +79.2% |
| Q1 2015 | $11,884,000 | -20.2% | 8,000,000 | -26.6% | 0.30% | -17.5% |
| Q4 2014 | $14,898,000 | +37.8% | 10,894,000 | +29.8% | 0.36% | +31.8% |
| Q3 2014 | $10,812,000 | +320.7% | 8,394,000 | +319.7% | 0.27% | +341.9% |
| Q2 2014 | $2,570,000 | – | 2,000,000 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Southpaw Asset Management LP | 20,000,000 | $17,675,000 | 25.38% |
| INCOME RESEARCH & MANAGEMENT | 23,109,000 | $20,278,000 | 5.29% |
| Fore Capital, LLC | 5,000,000 | $4,430,000 | 1.71% |
| RIVERHEAD CAPITAL MANAGEMENT LLC | 20,000,000 | $17,603,000 | 0.74% |
| ARISTEIA CAPITAL, L.L.C. | 18,500,000 | $16,361,000 | 0.70% |
| ZAZOVE ASSOCIATES LLC | 11,153,000 | $9,843,000 | 0.58% |
| BASSO CAPITAL MANAGEMENT, L.P. | 3,600,000 | $3,182,000 | 0.52% |
| CSS LLC/IL | 10,450,000 | $9,240,000 | 0.45% |
| Lombard Odier Asset Management (Europe) Ltd | 7,950,000 | $7,038,000 | 0.44% |
| Wellesley Asset Management | 6,740 | $5,948,000 | 0.31% |